TrialThe patient2021

Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).

Vasiliki Chounta et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.